Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
The Global Age-related Macular Degeneration Market was valued at USD 10.4 billion in 2023 and is expected to grow at a CAGR of 9.8% from 2024 to 2032. AMD is a progressive eye condition that affects central vision due to damage to the macula, the part of the retina responsible for sharp and direct vision. This condition primarily impacts older adults, becoming increasingly prevalent as the global population ages.
The market is categorized by product into treatments such as Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and others. Eylea dominated the market in 2023, generating USD 4.4 billion in revenue. Its widespread adoption stems from proven clinical efficacy, consistent safety results, and the flexibility of monthly or bi-monthly dosing options. This adaptability improves patient compliance, which is essential for managing chronic conditions like AMD.
AMD is further classified by disease type into wet and dry AMD. Wet AMD, which accounted for USD 8.5 billion in revenue in 2023, represents the leading cause of vision impairment among older adults. This disease involves abnormal blood vessel growth beneath the retina, resulting in fluid leakage and central vision loss. Treatments targeting vascular endothelial growth factor (VEGF) are the primary intervention for controlling disease progression. The rising global aging population, coupled with increasing life expectancy, has led to a surge in wet AMD cases, intensifying the need for effective, vision-preserving therapies. Innovations addressing the burden of frequent injections are gaining traction, offering patients more convenient dosing schedules and improving treatment adherence.
Regionally, the U.S. market accounted for USD 4.2 billion in 2023 and is anticipated to grow at a CAGR of 9.9% during the forecast period. The increasing elderly population in the U.S. drives demand for advanced AMD treatment options. With a robust biopharmaceutical industry, the country is at the forefront of developing innovative AMD therapies, including gene therapies, extended-release drug formulations, and combination treatments. These advancements aim to provide more effective and accessible solutions for managing AMD as its prevalence continues to rise.
The market is categorized by product into treatments such as Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and others. Eylea dominated the market in 2023, generating USD 4.4 billion in revenue. Its widespread adoption stems from proven clinical efficacy, consistent safety results, and the flexibility of monthly or bi-monthly dosing options. This adaptability improves patient compliance, which is essential for managing chronic conditions like AMD.
AMD is further classified by disease type into wet and dry AMD. Wet AMD, which accounted for USD 8.5 billion in revenue in 2023, represents the leading cause of vision impairment among older adults. This disease involves abnormal blood vessel growth beneath the retina, resulting in fluid leakage and central vision loss. Treatments targeting vascular endothelial growth factor (VEGF) are the primary intervention for controlling disease progression. The rising global aging population, coupled with increasing life expectancy, has led to a surge in wet AMD cases, intensifying the need for effective, vision-preserving therapies. Innovations addressing the burden of frequent injections are gaining traction, offering patients more convenient dosing schedules and improving treatment adherence.
Regionally, the U.S. market accounted for USD 4.2 billion in 2023 and is anticipated to grow at a CAGR of 9.9% during the forecast period. The increasing elderly population in the U.S. drives demand for advanced AMD treatment options. With a robust biopharmaceutical industry, the country is at the forefront of developing innovative AMD therapies, including gene therapies, extended-release drug formulations, and combination treatments. These advancements aim to provide more effective and accessible solutions for managing AMD as its prevalence continues to rise.
Report Content
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of AMD
3.2.1.2 Growth in aging population
3.2.1.3 Advancements in treatment options
3.2.1.4 Increased awareness and early diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Risk of complications from intravitreal injections
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Patent analysis
3.8 Pipeline analysis
3.9 Clinical trial landscape
3.10 Porter’s analysis
3.11 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Eylea
5.3 Lucentis
5.4 Beovu
5.5 Vabysmo
5.6 Syfovre
5.7 Avastin
5.8 Other products
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DISEASE TYPE, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Wet AMD
6.3 Dry AMD
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY AGE GROUP, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 50–64 years
7.3 65–74 years
7.4 75 and above
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Specialty pharmacies
8.4 E-commerce
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
CHAPTER 10 COMPANY PROFILES
10.1 Adverum Biotechnologies
10.2 Alkeus Pharmaceuticals
10.3 Amgen
10.4 Astellas Pharma
10.5 Bausch Health Companies
10.6 Bayer AG
10.7 Biogen
10.8 Coherus BioSciences
10.9 F. Hoffmann-La Roche
10.10 Kodiak Sciences
10.11 Novartis AG
10.12 Pfizer
10.13 Regeneron Pharmaceuticals
10.14 Sandoz Group AG
10.15 STADA Arzneimittel AG
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of AMD
3.2.1.2 Growth in aging population
3.2.1.3 Advancements in treatment options
3.2.1.4 Increased awareness and early diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Risk of complications from intravitreal injections
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Patent analysis
3.8 Pipeline analysis
3.9 Clinical trial landscape
3.10 Porter’s analysis
3.11 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY PRODUCT, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Eylea
5.3 Lucentis
5.4 Beovu
5.5 Vabysmo
5.6 Syfovre
5.7 Avastin
5.8 Other products
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY DISEASE TYPE, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Wet AMD
6.3 Dry AMD
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY AGE GROUP, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 50–64 years
7.3 65–74 years
7.4 75 and above
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Specialty pharmacies
8.4 E-commerce
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
CHAPTER 10 COMPANY PROFILES
10.1 Adverum Biotechnologies
10.2 Alkeus Pharmaceuticals
10.3 Amgen
10.4 Astellas Pharma
10.5 Bausch Health Companies
10.6 Bayer AG
10.7 Biogen
10.8 Coherus BioSciences
10.9 F. Hoffmann-La Roche
10.10 Kodiak Sciences
10.11 Novartis AG
10.12 Pfizer
10.13 Regeneron Pharmaceuticals
10.14 Sandoz Group AG
10.15 STADA Arzneimittel AG
